173 related articles for article (PubMed ID: 3149223)
21. Valproic acid and phenobarbital blood levels during the first month of treatment with the ketogenic diet.
Coppola G; Verrotti A; D'Aniello A; Arcieri S; Operto FF; Della Corte R; Ammendola E; Pascotto A
Acta Neurol Scand; 2010 Oct; 122(4):303-7. PubMed ID: 21077847
[TBL] [Abstract][Full Text] [Related]
22. Effect of valproate on free plasma phenytoin concentrations.
Tsanaclis LM; Allen J; Perucca E; Routledge PA; Richens A
Br J Clin Pharmacol; 1984 Jul; 18(1):17-20. PubMed ID: 6430316
[TBL] [Abstract][Full Text] [Related]
23. Serum protein binding of diphenylhydantoin in man. II. Interaction with sodium valproate in epileptic patients.
Gatti G; Lecchini S; Frigo GM; Visintini D; Calzetti S; Lombardi M; Cattaino G
Farmaco Prat; 1979 Jan; 34(1):46-8. PubMed ID: 378689
[No Abstract] [Full Text] [Related]
24. Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate.
Kober A; Olsson Y; Sjöholm I
Mol Pharmacol; 1980 Sep; 18(2):237-42. PubMed ID: 6775182
[No Abstract] [Full Text] [Related]
25. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparison of two prediction methods.
Kerrick JM; Wolff DL; Graves NM
Ann Pharmacother; 1995 May; 29(5):470-4. PubMed ID: 7655129
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients.
Garzón P; González-Cornejo S; Román-Maldonado S; Navarro-Ruiz A
Gen Pharmacol; 1985; 16(4):411-3. PubMed ID: 2412936
[TBL] [Abstract][Full Text] [Related]
27. [Changes of body mass index and plasma galanin in children with epilepsy following valproate sodium treatment].
Wang KL; Shi RF; Tang HX
Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jun; 12(6):488-9. PubMed ID: 20540863
[No Abstract] [Full Text] [Related]
28. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
Ueshima S; Aiba T; Ishikawa N; Sato T; Kawasaki H; Kurosaki Y; Ohtsuka Y; Sendo T
J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
[TBL] [Abstract][Full Text] [Related]
29. [Determination of N-Dipropylacetamide serum concentration and its clinical significance in epileptic children].
Shi FL
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1986 Aug; 19(4):217-20. PubMed ID: 3095059
[No Abstract] [Full Text] [Related]
30. [Experiences with sodium 2-propyl valerate (Depakine) in the treatment of epilepsy].
Trompetter-van Woerden ML; van der Zwan A
Ned Tijdschr Geneeskd; 1977 Apr; 121(14):578-90. PubMed ID: 323732
[No Abstract] [Full Text] [Related]
31. Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy.
Shakir RA; Johnson RH; Lambie DG; Melville ID; Nanda RN
Epilepsia; 1981 Feb; 22(1):27-33. PubMed ID: 6781888
[TBL] [Abstract][Full Text] [Related]
32. Serial free and plasma valproic acid and phenytoin monitoring and drug interactions.
Haidukewych D; Rodin EA
Ther Drug Monit; 1981; 3(3):303-7. PubMed ID: 6798720
[TBL] [Abstract][Full Text] [Related]
33. [Phenytoin determination in blood in epileptic children].
Walther H; Meyer FP; Leuschner U
Kinderarztl Prax; 1978 Jul; 46(7):364-74. PubMed ID: 682440
[No Abstract] [Full Text] [Related]
34. The effect of chronic carbamazepine, valproic acid and phenytoin medication on the periodontal condition of epileptic children and adolescents.
Galas-Zgorzalewicz B; Borysewicz-Lewicka M; Zgorzalewicz M; Borowicz-Andrzejewska E
Funct Neurol; 1996; 11(4):187-93. PubMed ID: 8934150
[TBL] [Abstract][Full Text] [Related]
35. [Leptilan. Dissolution, bioavailability and first therapeutic results in children with different epilepsy forms].
Windorfer A; Hermannsdörfer-Tröltzsch G; Kienholz M; Maier-Lenz H; Löhr W; Stoll KD
Fortschr Med; 1981 Oct; 99(37):1516-22. PubMed ID: 6795098
[No Abstract] [Full Text] [Related]
36. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy.
Lenn NJ; Robertson M
Neurology; 1992 May; 42(5):988-90. PubMed ID: 1579255
[TBL] [Abstract][Full Text] [Related]
37. [Daily plasma fluctuations of diphenylhydantoin in patients treated with diphenylhydantoin and sodium valproate].
Pisani F; Di Perri R
Acta Neurol Quad (Napoli); 1981; 42():61-3. PubMed ID: 6791452
[No Abstract] [Full Text] [Related]
38. Kinetics of intravenous phenytoin in children.
Koren G; Brand N; Halkin H; Dany S; Shahar E; Barzilay Z
Pediatr Pharmacol (New York); 1984; 4(1):31-8. PubMed ID: 6739185
[TBL] [Abstract][Full Text] [Related]
39. [Monitoring of plasma diphenylhydantoin levels in epileptic patients].
Lezama-Dávila CM; Olmos-García de Alba G; López-Anaya A; Valarezo-Crespo F
Bol Med Hosp Infant Mex; 1983 May; 40(5):256-61. PubMed ID: 6871012
[No Abstract] [Full Text] [Related]
40. Role of combination of valproic acid with diphenylhydantoin and carbamazepine in the management of intractable seizures.
Ashok PP; Maheshwari MC
J Assoc Physicians India; 1984 Jul; 32(7):565-7. PubMed ID: 6438054
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
